Skip to search formSkip to main contentSkip to account menu

L 368899

Known as: Butanamide, 2-amino-N-(7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo(2.2.1)hept-2-yl)-4-(methylsulfonyl)-, (1S-(1alpha,2alpha(R*),4beta))-, L 368,899, L-368899 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Oxytocin is currently being considered as a novel therapeutic for anxiety disorders due to its ability to promote affiliative… 
2014
2014
Centrally acting oxytocin (OT) inhibits feeding. Recent evidence suggests a link between OT and control of carbohydrate and… 
Highly Cited
2014
Highly Cited
2014
A growing number of studies have demonstrated that oxytocin (OT) plays an analgesic role in modulation of nociception and pain… 
Highly Cited
2010
Highly Cited
2010
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal enterocytes during the… 
Review
1995
Review
1995
From a targeted screening effort and medicinal chemistry program, L-368,899 was selected as the first orally-active oxytocin (OT…